Pennystock Hub is promoting RGBP for Thursday, 3/2/2017
Lets see what happens.
Today's (3-2) featured company, Regen BioPharma Inc. (RGBP) , has found itself doing discovery phase arrangements with one of the BIGGEST companies in the industry! It just so happens that the industry RGBP is in, is the Biotech space; one of the hottest and most active sectors of the market today!
RGBP Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company!
In case you're not familiar, Eli Lilly and Company is an $88Billion company, publicly trading RIGHT NOW at roughly $84/share..why would a company like this even be in the same room as (RGBP) ? In our opinion, the answer is opportunity.
The two companies entered into a definitive agreement with Eli Lilly and Company, which allows (RGBP) to receive compounds from Lilly for drug discovery purposes and allows (RGBP) to share structural information on compounds of mutual interest.
The agreement also grants to Lilly an option to negotiate an agreement with Regen including but not restricted to a compound purchase agreement, a license agreement, or a research collaboration agreement for further research and development of material of mutual interest.
Could (RGBP) Be Setting Up For A Major Move In The Very Near Term?
(RGBP) is working to develop immunotherapies and cancer stem cell therapies for rapid commercialization. The Company is specifically focused on human therapies that address unmet medical needs. (RGBP) has already begun the process of optimizing its lead compounds, RG-NA01, RG-NA02, RG-NI01 and RG-NI02, which are inhibitors and activators of NR2F6; potentially a very important immune cell inhibitor or checkpoint & specialized cancer stem cell.
Basically (RGBP) is working to identify what interferes with NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system...did we mention that one of the biggest companies in biotech has tapped (RGBP) in order to further the investigation and to identify activators and inhibitors of this NR2F6 protein?
Eli Lilly has been behind some of the most famous medical developments out there and we're willing to bet that you've heard of them: Cymbalta...Prozac...what about Cia lis? And now we're looking at a micro-cap company aligned directly with this company through this discovery program!
Issued US Patent # 9091696 was granted to (RGBP) and covers means of screening small molecules such as is being done in this program.
Cancer, as well as autoimmune diseases such as lupus, rheumatoid arthritis and irritable bowel syndrome, is likely to be controlled by modifying NR2F6 activity according to the company.
Market For Immunotherapy Drugs: $201 Bil. by 2021
According to ResearchAndMarkets, the global immunotherapy drugs market is projected to reach $201.52 Billion by 2021 from $108.41 Billion in 2016, a compounded annual growth rate of 13.5% during the forecast period of 2016 to 2021.
North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.
And as far as cancer immunotherapy, that market alone is projected to reach $119.39 Billion by 2021!
Project Pipeline Already Has The Attention Of The FDA
If you have seen other small cap biotechs, their pipelines may be small, one therapy at times. Not only does (RGBP) have multiple treatments in their pipeline but they've already received clearance to proceed to PHASE I / II CLINICAL TRIALS!
HemaXellerate Aplastic
Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning. HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow and has its Investigational New Drug Application already cleared by the ?United States Food and Drug Administration cleared (IND #15376)
dCellVax
Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
DiffronC
Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
Small Molecule Targeting Cancer Stem Cell Genes
Small Molecule targeting of the cancer stem cell is the process of “coaxing” the cancer stem cell to turn into a normal cell. Regen has identified and filed patents on a novel gene controlling the process of cancer stem cell differentiation.
Telomeres & Genomic Integrity
Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
Bottom Line
A company like this doesn't come around every day. For such a small company to be on the radar screen of a "Big Boy Biotech" is one thing but to be directly working alongside a powerhouse like Eli Lilly could put (RGBP) head and shoulders above its competition.
Not only does the company have an active pipeline with Phase trials potentially right on the horizon but future possibilities for licensing and beyond could be key indicators signaling that this could be one of the smaller cap biotechs to be watching right now!
We want to stress that being ready at the opening bell could be key to watching for a potential breakout, especially with a biotech alert like this. These can become active right out of the gate and it all starts at 9:30AM EST on Thursday (3-2). So if you choose, pull up (RGBP) , do your DD, and be ready for the opening bell, this morning (3-2)! Stay tuned.
Want Instant Updates on Our Alerts?
